Vertex (VRTX) EVP and CMO Carmen Bozic sells 2,329 shares in pre-set 10b5-1 trade

Rhea-AI Filing Summary

Vertex Pharmaceuticals executive Carmen Bozic reported an open-market sale of company stock. On March 13, 2026, Dr. Bozic sold 2,329 shares of Vertex common stock at a price of $481.79 per share, as part of routine portfolio activity.

After this transaction, Dr. Bozic directly held 35,405 shares of Vertex common stock, indicating she retains a substantial ownership stake. The sale was carried out under a pre-established Rule 10b5-1 trading plan, meaning it was scheduled in advance under company-approved guidelines rather than timed opportunistically.

Insights

Equity compensation and insider-trading analyst

Routine, pre-planned executive stock sale with a sizable remaining stake.

Executive vice president and CMO Carmen Bozic sold 2,329 shares of Vertex Pharmaceuticals common stock at $481.79 per share in an open-market transaction. This is a straightforward disposition of existing shares, with no options exercised or derivatives involved.

The filing shows 35,405 shares held directly after the sale, so the transaction represents only a small portion of her visible holdings, suggesting routine liquidity rather than a major change in exposure. The footnote explains the trade was executed under a Rule 10b5-1 trading plan entered on November 20, 2025, indicating it was pre-scheduled and not driven by near-term information.

Because the sale is modest relative to her remaining position and conducted under a company-approved plan, it generally carries limited informational value about Vertex’s outlook. Future Form 4 filings will continue to detail any additional transactions under the same trading plan.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bozic Carmen

(Last) (First) (Middle)

C/O VERTEX PHARMACEUTICALS INCORPORATED

50 NORTHERN AVENUE

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP and CMO

3. Date of Earliest Transaction (Month/Day/Year)
03/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/13/2026		S(1)		2,329	D	$481.79	35,405	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 11/20/2025.

Remarks:

	/s/ Christiana Stevenson, Attorney-in-Fact	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Vertex (VRTX) executive Carmen Bozic report in this Form 4?

Dr. Carmen Bozic reported an open-market sale of 2,329 shares of Vertex common stock at $481.79 per share. The transaction reflects a partial reduction of her position while she continues to hold a significant number of shares afterward.

How many Vertex (VRTX) shares does Carmen Bozic still hold after the sale?

After the reported transaction, Dr. Carmen Bozic directly holds 35,405 shares of Vertex common stock. This indicates the 2,329-share sale was only a fraction of her total holdings and she maintains substantial equity exposure to the company.

Was the Carmen Bozic Vertex (VRTX) stock sale part of a 10b5-1 trading plan?

Yes. The filing states the transaction was made pursuant to Dr. Bozic’s company-approved trading plan under Rule 10b5-1, entered on November 20, 2025. Such plans pre-schedule trades, reducing the likelihood that timing reflects short-term insider views.

What type of transaction did Carmen Bozic execute in Vertex (VRTX) shares?

The Form 4 describes the event as an open-market sale of common stock, coded as an “S” transaction. That means Dr. Bozic sold existing shares directly into the market rather than exercising options, receiving a grant, or making a private transfer.

Does the Carmen Bozic Form 4 involve Vertex (VRTX) stock options or derivatives?

No. The reported transaction covers only non-derivative common stock, with no associated option exercises or derivative conversions. The derivative section of the filing is empty, indicating this sale did not change any outstanding option or derivative positions.

How large is Carmen Bozic’s Vertex (VRTX) stock sale relative to her holdings?

Dr. Bozic sold 2,329 shares while holding 35,405 shares afterward, so the sale represents a relatively small portion of her disclosed stake. This scale and the 10b5-1 plan context suggest a routine liquidity event rather than a major shift in ownership.